Showing results (661-670 of 758) with videos related to
Sort By:
Pageof 76
The Journal of Cell Biology|July 18, 2020
EGF receptor-mediated FUS phosphorylation promotes its nuclear translocation and fibrotic signalingManuel Chiusa, Wen Hu, Jozef Zienkiewicz, et al.Journal of the American Society of Nephrology : JASN|April 12, 2014
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyDick de Zeeuw, Blai Coll, Dennis Andress, et al.Lancet (London, England)|September 28, 2025
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 studyDavid Kavanagh, Andrew S Bomback, Marina Vivarelli, et al.Blood|April 25, 2012
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpuraLuca A Lotta, Haifeng M Wu, Ian J Mackie, et al.Clinical Journal of the American Society of Nephrology : CJASN|July 9, 2015
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic NephropathyDonald E Kohan, Hiddo J Lambers Heerspink, Blai Coll, et al.Clinical Journal of the American Society of Nephrology : CJASN|July 3, 2010
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotypeMarina Noris, Jessica Caprioli, Elena Bresin, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2009
The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney graftsMarina Noris, Paola Cassis, Nadia Azzollini, et al.Diabetes, Obesity & Metabolism|December 17, 2016
Comparison of exposure response relationship of atrasentan between North American and Asian populationsHiddo J L Heerspink, Hirofumi Makino, Dennis Andress, et al.Kidney International Reports|February 24, 2025
Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 GlomerulopathyCarla M Nester, Ute Eisenberger, Alexandre Karras, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.Pageof 76